SNO 2021

ONC201 Shows Clinical Efficacy in H3 K27M-Mutated Diffuse Midline Glioma

By

Jonathan Goodman, MPhil

November 29, 2021

Among patients with a performance status of less than 80, 20.6% had an improvement in this metric.

Image of glioblastoma.

Adding Nivolumab to Standard Care Does Not Improve Survival in Glioblastoma

By

Jonathan Goodman, MPhil

November 24, 2021

The median PFS was 10.6 months in the nivolumab group and 10.3 months in the placebo group.

Image of woman talking to doctor through tablet.

Neuro-Oncology Patient Satisfaction Maintained During COVID-19 Pandemic

By

Leah Lawrence

November 23, 2021

Patient satisfaction scores before the pandemic were comparable to scores during the pandemic.

Next post in Brain Cancer

Elderly patient in a hospital bed.

One-Third of Patients May Not Recover From TMZ-Induced Aplastic Anemia